Exhibit 99.1 Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates CONSHOHOCKEN, Pa., July 30, 2026 – Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today reports second-quarter 2026 financial results and provides corporate updates. Bill Sibold, Chief Executive Officer of Madrigal, stated: "Madrigal delivered another outstanding qua ...